Anzeige
Mehr »
Samstag, 05.07.2025 - Börsentäglich über 12.000 News
LiquidLink startet Bitcoin Lightning- und XRP-ILP-Nodes - Aufbau des Rückgrats der tokenisierten Finanzwelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
360 Leser
Artikel bewerten:
(1)

Vanguard Laboratories Selects PreciseMDX to Improve the Laboratory Testing Experience, Achieve Better Visibility and Efficiency

Platform addition is the latest integration by the Salt Lake City-based molecular lab set to improve the patient experience during PCR and diagnostic testing

PALO ALTO, CA / ACCESSWIRE / April 22, 2022 / PreciseMDX, a leader in transformative digital health experiences, and Vanguard Laboratories, a PCR molecular lab, today announced the integration of the PreciseMDX digital health platform to drive, track and improve testing throughout the patient journey. The customizable PreciseMDX platform integrates seamlessly with Vanguard Laboratories' existing laboratory information management (LIM) system, serving as one cohesive unit to enhance PCR and diagnostic testing operations.

https://storage.googleapis.com/accesswire/media/698473/LabPhoto.jpeg

"According to the Centers for Disease Control and Prevention (CDC), 70 percent of medical decisions depend on laboratory results. It's labs like Vanguard that are working hard to deliver those results faster and more accurately than ever before," said Mark Dorner, co-founder and CEO of PreciseMDX. "The PreciseMDX digital health ecosystem is armed with best-in-class digital health software for testing and population health management, which allow our customers to focus on expanding their business through better patient care. Our platform supports the diverse types of PCR and diagnostic testing provided by Vanguard, helping them meet patients where they are with customizable journeys from start to finish."

PreciseMDX takes the complexity out of high-volume testing programs so lab customers can focus on producing quick, quality results for their patients. The platform allows diagnostic laboratories and healthcare systems to lower operational costs on hardware, software development and maintenance, shipping, and fulfillment while raising profitability. PreciseMDX's platform was designed and built following the National Institute for Standards and Technology (NIST) security framework to support HIPAA, PIPEDA, GDPR, and other international standards.

"Turnaround time is crucial to providing the best patient care. That's why we've invested heavily in advanced diagnostic testing technology to cut down valuable transition time from the time the patient is tested to the time results are received," said Nathan Keele, CEO of Vanguard Laboratories. "Accuracy is even more important, which is why we focus solely on PCR testing versus the outdated culturing methods that many labs still rely on. We recognize that it's time for patients to have greater visibility and insight into the testing process, and with the help of PreciseMDX's digital health solution, we're making that happen."

About PreciseMDX

PreciseMDX empowers labs to deliver a transformative digital health experience that providers and patients expect. Much more than a portal, the PreciseMDX platform creates an end-to-end digital health ecosystem that automates and simplifies every step of the diagnostic testing experience, leveraging the ubiquitous power and convenience of mobile device technology. PreciseMDX brings more than 20 years of digital transformation know-how from prior roles in healthcare, government, and other industries to solve customers' biggest data management and patient engagement needs. Founded in 2020, the Silicon Valley-based company works with customers worldwide including the United States, Switzerland and Canada. For more information, visit www.precisemdx.com.

https://storage.googleapis.com/accesswire/media/698473/VanguardLabs.png

About Vanguard Laboratories

Vanguard Laboratories was founded to lead the next generation of clinical testing. The company delivers full-service molecular PCR testing solutions to long-term care facilities, physicians' offices, hospitals, schools, and businesses across the country. Their product catalog spans a variety of molecular and genetic testing including COVID Antigen testing, respiratory panels, UTI panels, wound care, vaginal microbiota, sexually transmitted infections and fungal. For more information, email admin@lab-vanguard.com or visit www.vanguardlaboratories.com.

Press contact information:
Tom Testa
Anderson Interactive on behalf of PreciseMDX
617-872-0184
tom@andersoni.com

SOURCE: PreciseMDX



View source version on accesswire.com:
https://www.accesswire.com/698473/CORRECTION-Vanguard-Laboratories-Selects-PreciseMDX-to-Improve-the-Laboratory-Testing-Experience-Achieve-Better-Visibility-and-Efficiency

© 2022 ACCESS Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.